Cargando…

Gluco-metabolic effects of oral and intravenous alcohol administration in men

BACKGROUND: Ingestion of the calorically dense compound alcohol may cause metabolic disturbances including hypoglycaemia, hepatic steatosis and insulin resistance, but the underlying mechanisms are uncertain. The gastrointestinal tract is well recognised as a major influencer on glucose, protein and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanng, Amalie R, Gasbjerg, Lærke S, Bergmann, Natasha C, Bergmann, Sigrid, Helsted, Mads M, Gillum, Matthew P, Hartmann, Bolette, Holst, Jens J, Vilsbøll, Tina, Knop, Filip K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790903/ https://www.ncbi.nlm.nih.gov/pubmed/31518994 http://dx.doi.org/10.1530/EC-19-0317

Ejemplares similares

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomised, placebo-controlled clinical trial
por: Helsted, Mads M, et al.
Publicado: (2023)

LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men
por: Hagemann, Christoffer A., et al.
Publicado: (2022)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course
por: Mikkelsen, Kristian H., et al.
Publicado: (2018)

Protocol for assessing the effects of exogenous hormone administration on human postprandial glucose metabolism, appetite sensations, and food intake
por: Hagemann, Christoffer A., et al.
Publicado: (2023)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Intravenous Treatment of Some Epileptics with Calcium Chloride and Gluco-Calcium
Publicado: (1929)

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty
por: Plamboeck, Astrid, et al.
Publicado: (2013)

The Role of Incretins on Insulin Function and Glucose Homeostasis
por: Holst, Jens Juul, et al.
Publicado: (2021)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Protocol for a 30-day randomised, parallel-group, non-inferiority, controlled trial investigating the effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19: the RASCOVID-19 trial
por: Kliim-Hansen, Vivian, et al.
Publicado: (2022)

The effect of curcumin on hepatic fat content in individuals with obesity
por: Hellmann, Pernille H., et al.
Publicado: (2022)

Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study
por: Hansen, Nina L., et al.
Publicado: (2020)

GLINT: GlucoCEST in neoplastic tumors at 3 T—clinical results of GlucoCEST in gliomas
por: Bender, Benjamin, et al.
Publicado: (2021)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity
por: Hellmann, Pernille H, et al.
Publicado: (2023)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Accuracy Assessment of the GlucoMen(®) Day CGM System in Individuals with Type 1 Diabetes: A Pilot Study
por: Hochfellner, Daniel A., et al.
Publicado: (2022)

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
por: Hare, Kristine J., et al.
Publicado: (2010)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Hansen, Katrine B, et al.
Publicado: (2010)

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
por: Gluud, Lise L, et al.
Publicado: (2014)

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons
por: Dalsgaard, Niels B., et al.
Publicado: (2017)

Secretion of parathyroid hormone may be coupled to insulin secretion in humans
por: Sass, Marie Reeberg, et al.
Publicado: (2020)

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies
por: Calanna, Salvatore, et al.
Publicado: (2013)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018)

Hypoglycaemia and cardiac arrhythmias in diabetes
por: Andersen, Andreas, et al.
Publicado: (2020)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
por: Junker, Anders Ellekær, et al.
Publicado: (2014)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
por: Lindquist, Peter, et al.
Publicado: (2022)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

N‐terminal alterations turn the gut hormone GLP‐2 into an antagonist with gradual loss of GLP‐2 receptor selectivity towards more GLP‐1 receptor interaction
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2022)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_efejftmna4srh5i87jvk3vqcjb